OPTIMIZING ORAL ISOTRETINOIN TREATMENT OF ACNE
Main Article Content
Abstract
Acne vulgaris is one of the most common skin diseases especially in adolescents with pilosebaceous units inflammatory caused by several factors. Nowadays, although there are many methods are used for acne treatment, isotretinoin remains the most efficacious treatment for severe acne as well as many moderate cases that are unresponsive to other treatment modalities. Besides the efficacy of isotretinoin brings to us, adverse effects and the patient management in the treatment course that are essential issue. By searching reputable journals such as JAMA, Pubmed, Google Scholar, Science Direct, this article helps the practitioner optimize isotretinoin use for acne, this article outlines updated information about the indication, dose isotretinoin regimen, reported data on factors that influence relapse after oral isotretinoin therapy, reviews the recommended guidelines for monitoring and summarizes adverse effects and prevention which contributes to open a new trend about the most effective treatment time and isotretinoin dose in acne treatment.
Keywords
acne, isotretinoin
Article Details
References
2. Afsaneh SB., Mohammadreza Ghassemi et al (2020), Systematic review of low-dose isotretinoin for treatment of acne vulgaris: Focus on indication, dosage, regimen, efficacy, safety, satisfaction, and follow up, based on clinical studies, Dermatol Ther, 34(1).
3. Ahmad HM. (2015), Analysis of clinical efficacy, side effects, and laboratory changes among patients with acne vulgaris receiving single versus twice daily dose of oral isotretinoin, Dermatol Ther, 28(3):151–7.
4. Akman A, Durusoy C, Senturk M (2007), Treatment of acne with intermittent and conventional isotretinoin: a randomized, controlled multicenter study. Arch Dermatol Res, 299(10):467–73.
5. Alison Layton (2009), The use of isotretinoin in acne, Dermato endocrinol, 1(3): 162–169.
6. Amichai B, Shemer A (2006), Low-dose isotretinoin in the treatment of acne vulgaris, J Am Acad Dermatol, 54(4):644–6.
7. Blasiak RC, Stamey CR (2013), High-dose isotretinoin treatment and the rate of retrial, relapse, and adverse effects in patients with acne vulgaris, JAMA Dermatol, 149(12):1392.
8. Brelsford M, Beute TC (2008), Preventing and managing the side effects of isotretinoin, Semin Cutan Med Surg, 27(3):197–206.
9. Gollnick HP, Bettoli V, et al (2016), A consensus-based practical and daily guide for the treatment of acne patients, J Eur Acad Dermatol Venereol, 30(9):1480–90.9
10. Greywal T, Zaenglein AL, et al (2017), Evidence-based recommendations for the management of acne fulminans and its ariants, J Am Acad Dermatol, 77(1):109–17.
11. James Q. Del Rosso (2012), Face to Face with Oral Isotretinoin, J Clin Aesthet Dermatol,
5(11): 17–24.
12. James J. Leyden, James Q. Del Rosso, et al (2014), The Use of Isotretinoin in the Treatment of Acne Vulgaris Clinical Considerations and Future Directions, J Clin Aesthet Dermatol, 7(2 Suppl): S3–S21.
13. Kaymak Y, Illter N. (2006), The efectiveness of intermittent isotretinoin treatment in mild or moderate acne, J Eur Acad Dermatol Venereol, 20:1256–60.
14. Krishna S, Kim C, Kim J (2012), The efect of omega-3 fatty acid on triglyceride levels in patients using isotretinoin, J Am Acad Dermatol, 66(4 Suppl 1):AB19.
15. Layton AM, Knaggs H, Taylor J, Cunlife WJ (1993), Isotretinoin for acne vulgaris—10 years later: a safe and succesful treatment, J Dermatol, 108:333–43.
16. Lee YH., Scharnitz TP., Muscat Joshua et al (2016), Laboratory Monitoring During Isotretinoin Therapy for Acne: A Systematic Review and Meta-analysis, JAMA Dermatol, 152(1):35-44.
17. Megan N Landis (2020), Optimizing Isotretinoin Treatment of Acne: Update on Current Recommendations for Monitoring, Dosing, Safety, Adverse Effects, Compliance, and Outcomes, Am J Clin Dermatol, 21(3):411-419.
18. Rademaker M. (2016), Making sense of the effects of the cumulative dose of isotretinoin in acne vulgaris, Int J Dermatol, 55(5):518–23.
19. Roenigk HH (1988), Liver toxicity of retinoid therapy, J Am Acad Dermatol, 19(1 Pt 2):199–208.
20. Sardana K, Garg VK, Sehgal VN. (2009), Efficacy of fxed low-dose isotretinoin (20 mg, alternate days) with topical clindamycin gel in moderately severe acne vulgaris, J Eur Acad Dermatol Venereol, 23(5):556–60.
21. Spring, L. K., Krakowski, et al (2017), Isotretinoin and Timing of Procedural Interventions, JAMA Dermatology, 153(8), 802.
22. Stainforth JM, Layton AM (1993), Isotretinoin for the treatment of acne vulgaris: which factors may predict the need for more than one course?, Br J Dermatol, 129(3):297–301.
23. Tan J, Knezevic S, Boyal S (2016), Evaluation of evidence for acne remission with oral isotretinoin cumulative dosing of 120–150 mg/kg, J Cutan Med Surg, 20(1):13–20.
24. Truchuelo MT, Jiménez N (2015), Assessment of the efficacy and safety of a combination of 2 topical retinoids (RetinSphere) in maintaining post-treatment response of acne to oral isotretinoin, Actas Dermo-Sifiliográficas, 106(2):126–32.
25. Venkataram Mysore, Omprakash H., Mahadevappa, et al (2017), Standard Guidelines of Care: Performing Procedures in Patients on or Recently Administered with Isotretinoin, J Cutan Aesthet Surg, 10(4): 186–194.
26. Waldman A, Bolotin D, et al (2017), ASDS Guidelines Task Force, Dermatol Surg, 43(10):1249–62.
27. Webster GF, Webster TG (2017), Laboratory tests in patients treated with isotretinoin:
occurrence of liver and muscle abnormalities and failure of AST and ALT to predict liver abnormality, Dermatol Online J, 23(5):3.
28. Wolverton S. (2020), Comprehensive dermatologic drug therapy, 4th edit, Elsevier, pp.
245-259.